| Abstrakt: |
A recent study conducted at University Hospital Grenoble Alpes in France has found that despite the use of desensitization strategies in kidney transplant recipients, there is still a risk of antibody-mediated rejection. The study included 10 highly sensitized recipients who underwent desensitization therapy prior to transplantation. The researchers observed a decrease in donor-specific antibodies and certain B-cell subsets, but found that memory B cells and plasma cells persisted even up to 12 months after transplantation. The study suggests that targeting glycolysis, a metabolic process, in these cells may be a potential treatment strategy. [Extracted from the article] |
